The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.
This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.